Gene therapy effectiveness differs for neuronal survival and behavioral performance - PubMed

Gene therapy effectiveness differs for neuronal survival and behavioral performance

R G Phillips et al. Gene Ther. 2001 Apr.

Abstract

If neuronal gene therapy is to be clinically useful, it is necessary to demonstrate neuroprotection when the gene is introduced after insult. We now report equivalent neuronal protection if calbindin D(28K) gene transfer via herpes simplex virus amplicon vector occurs immediately, 30 min, or 1 h after an excitotoxic insult, but not after a 4 h delay. Behavioral performance was evaluated for immediate and 1 h delay groups using a hippocampal-dependent task. Despite equivalent magnitude and pattern of sparing of neurons with the immediate and 1 h delay approaches, the delay animals took a significantly longer time after insult to return to normal performance.

Similar articles

• Gene therapy with HSP72 is neuroprotective in rat models of stroke and epilepsy.

  Yenari MA, Fink SL, Sun GH, Chang LK, Patel MK, Kunis DM, Onley D, Ho DY, Sapolsky RM, Steinberg GK. Yenari MA, et al. Ann Neurol. 1998 Oct;44(4):584-91. doi: 10.1002/ana.410440403. Ann Neurol. 1998. PMID: 9778256

• Simultaneous glutamate and GABA(A) receptor agonist administration increases calbindin levels and prevents hippocampal damage induced by either agent alone in a model of perinatal brain injury.

  Hilton GD, Ndubuizu A, Nunez JL, McCarthy MM. Hilton GD, et al. Brain Res Dev Brain Res. 2005 Oct 6;159(2):99-111. doi: 10.1016/j.devbrainres.2005.07.007. Brain Res Dev Brain Res. 2005. PMID: 16125793

• Calbindin D28K gene transfer via herpes simplex virus amplicon vector decreases hippocampal damage in vivo following neurotoxic insults.

  Phillips RG, Meier TJ, Giuli LC, McLaughlin JR, Ho DY, Sapolsky RM. Phillips RG, et al. J Neurochem. 1999 Sep;73(3):1200-5. doi: 10.1046/j.1471-4159.1999.0731200.x. J Neurochem. 1999. PMID: 10461912

• Genetic analysis of neuronal physiology with defective herpes simplex virus vectors.

  Neve RL, Geller AI. Neve RL, et al. Adv Neurol. 1999;79:1027-32. Adv Neurol. 1999. PMID: 10514884 Review. No abstract available.

• "Exuberant" neuronal growth after brain damage in adult rats: the essential role of behavioral experience.

  Schallert T, Jones TA. Schallert T, et al. J Neural Transplant Plast. 1993 Jul-Sep;4(3):193-8. doi: 10.1155/NP.1993.193. J Neural Transplant Plast. 1993. PMID: 8018751 Free PMC article. Review. No abstract available.

Cited by

• The potential application of gene therapy in the treatment of traumatic brain injury.

  Shen F, Wen L, Yang X, Liu W. Shen F, et al. Neurosurg Rev. 2007 Oct;30(4):291-8; discussion 298. doi: 10.1007/s10143-007-0094-4. Epub 2007 Aug 9. Neurosurg Rev. 2007. PMID: 17687574 Review.

• Characterization of calretinin I-II as an EF-hand, Ca2+, H+-sensing domain.

  Palczewska M, Batta G, Groves P, Linse S, Kuznicki J. Palczewska M, et al. Protein Sci. 2005 Jul;14(7):1879-87. doi: 10.1110/ps.051369805. Epub 2005 Jun 3. Protein Sci. 2005. PMID: 15937279 Free PMC article.

• Combining glial cell line-derived neurotrophic factor gene delivery (AdGDNF) with L-arginine decreases contusion size but not behavioral deficits after traumatic brain injury.

  Degeorge ML, Marlowe D, Werner E, Soderstrom KE, Stock M, Mueller A, Bohn MC, Kozlowski DA. Degeorge ML, et al. Brain Res. 2011 Jul 27;1403:45-56. doi: 10.1016/j.brainres.2011.05.058. Epub 2011 Jun 2. Brain Res. 2011. PMID: 21672665 Free PMC article.

• Anti-apoptotic therapy with a Tat fusion protein protects against excitotoxic insults in vitro and in vivo.

  Ju KL, Manley NC, Sapolsky RM. Ju KL, et al. Exp Neurol. 2008 Apr;210(2):602-7. doi: 10.1016/j.expneurol.2007.12.008. Epub 2007 Dec 23. Exp Neurol. 2008. PMID: 18207142 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Medical

  • MedlinePlus Health Information